Novartis announces option exercise and merger proposal
Novartis is to exercise its option to purchase the remaining shares in Alcon, Inc., owned by Nestle S.A. at a weighted average price of US$180 per share in cash following the agreement between Nestle and Novartis in April 2008.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Recent Videos
Related Content
